CA2694122A1 - Central administration of stable formulations of therapeutic agents for cns conditions - Google Patents
Central administration of stable formulations of therapeutic agents for cns conditions Download PDFInfo
- Publication number
- CA2694122A1 CA2694122A1 CA2694122A CA2694122A CA2694122A1 CA 2694122 A1 CA2694122 A1 CA 2694122A1 CA 2694122 A CA2694122 A CA 2694122A CA 2694122 A CA2694122 A CA 2694122A CA 2694122 A1 CA2694122 A1 CA 2694122A1
- Authority
- CA
- Canada
- Prior art keywords
- therapeutic agent
- cns
- cns therapeutic
- human
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96655407P | 2007-07-25 | 2007-07-25 | |
| US60/966,554 | 2007-07-25 | ||
| PCT/US2008/009109 WO2009014762A1 (en) | 2007-07-25 | 2008-07-25 | Central administration of stable formulations of therapeutic agents for cns conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2694122A1 true CA2694122A1 (en) | 2009-01-29 |
Family
ID=40281688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2694122A Abandoned CA2694122A1 (en) | 2007-07-25 | 2008-07-25 | Central administration of stable formulations of therapeutic agents for cns conditions |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP2180884A4 (de) |
| AU (1) | AU2008279636A1 (de) |
| CA (1) | CA2694122A1 (de) |
| WO (1) | WO2009014762A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008095221A1 (en) | 2007-02-07 | 2008-08-14 | Gosforth Centre (Holdings) Pty Ltd | Treatment of adhd |
| WO2009151741A1 (en) * | 2008-04-01 | 2009-12-17 | The Regents Of The University Of Colorado | Methods and compositions for the intracerebroventricular administration of felbamate |
| EP2331088A4 (de) | 2008-08-06 | 2011-10-12 | Gosforth Ct Holdings Pty Ltd | Zusammensetzungen und verfahren zur behandlung von psychiatrischen erkrankungen |
| US11511035B2 (en) | 2016-07-28 | 2022-11-29 | Cerebral Therapeutics, Inc. | Implantable intraventricular sampling and infusion access device |
| US20190151239A1 (en) | 2016-07-28 | 2019-05-23 | Cerebral Therapeutics LLC | Infusing drug solution directly into brain fluid |
| AU2018354181A1 (en) | 2017-10-23 | 2020-03-12 | Cerebral Therapeutics LLC | High concentration valproic acid solutions for treating neurological disorders |
| EP3520803A1 (de) * | 2018-01-31 | 2019-08-07 | Zarodex Therapeutics Limited | Neuartige verwendungen |
| TW202114655A (zh) | 2019-08-14 | 2021-04-16 | 瑞士商辛鐵堤卡公司 | 左乙拉西坦(levetiracetam)之鞘內投藥 |
| IL299827B1 (en) | 2020-07-15 | 2026-04-01 | Cerebral Therapeutics Inc | A medical system that includes two access ports |
| US12102636B2 (en) * | 2021-02-11 | 2024-10-01 | Medtronic, Inc. | Administration of antipsychotics |
| US12605537B2 (en) | 2022-02-15 | 2026-04-21 | Biogen Ma Inc. | Implantable medical device for use with or having recording electrode |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5594190A (en) * | 1989-06-02 | 1990-12-06 | Ciba-Geigy Ag | Intravenous solutions with a rapid onset of action |
| FR2716680B1 (fr) * | 1994-02-25 | 1996-04-05 | Adir | Nouveaux dérivés de benzodioxane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| US20050090548A1 (en) * | 2003-10-23 | 2005-04-28 | Medtronic, Inc. | Intrathecal gabapentin for treatment of epilepsy |
| CA2605651C (en) * | 2005-04-26 | 2013-10-08 | Ambryx Biotechnology, Inc. | Compositions and methods for treating or preventing overweight or obesity with zinc-charged protein fragments |
| US20070149466A1 (en) * | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| JP2009523802A (ja) * | 2006-01-17 | 2009-06-25 | リージェンツ オブ ザ ユニバーシティー オブ コロラド | Cns状態のための治療剤の安定製剤の中枢投与 |
-
2008
- 2008-07-25 AU AU2008279636A patent/AU2008279636A1/en not_active Abandoned
- 2008-07-25 CA CA2694122A patent/CA2694122A1/en not_active Abandoned
- 2008-07-25 WO PCT/US2008/009109 patent/WO2009014762A1/en not_active Ceased
- 2008-07-25 EP EP08794800.6A patent/EP2180884A4/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008279636A1 (en) | 2009-01-29 |
| EP2180884A1 (de) | 2010-05-05 |
| WO2009014762A1 (en) | 2009-01-29 |
| EP2180884A4 (de) | 2013-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2694122A1 (en) | Central administration of stable formulations of therapeutic agents for cns conditions | |
| AU2007207606A1 (en) | Central administration of stable formulations of therapeutic agents for CNS conditions | |
| US6261582B1 (en) | Surgical method and composition therefor | |
| Bell et al. | S‐adenosylmethionine blood levels in major depression: changes with drug treatment | |
| US6599906B1 (en) | Method of local anesthesia and analgesia | |
| ES2307975T3 (es) | Composiciones analgesicas que comprenden antagonistas del receptor de nmda y cloruro de benzalconio. | |
| Allen et al. | Time course and role of morphine dose and concentration in intrathecal granuloma formation in dogs: a combined magnetic resonance imaging and histopathology investigation | |
| EP1727549A1 (de) | Intranasale benzodiazepin-zusammensetzungen | |
| US20140100183A1 (en) | Central administration of stable formulations of therapeutic agents for cns conditions | |
| US10076522B2 (en) | Systems and methods for treating bacterial infection | |
| KR20190035965A (ko) | 연장된 지속 기간의 국소 마취제 제형 | |
| EP2273993A1 (de) | Verfahren und zusammensetzungen zur intrazerebroventrikulären verabreichung von felbamat | |
| Rodriguez-Navarro et al. | Potentiation of local anesthetic activity of neosaxitoxin with bupivacaine or epinephrine: development of a long-acting pain blocker | |
| Natalini et al. | Analgesic and cardiopulmonary effects of epidural romifidine and morphine combination in horses | |
| US9504666B2 (en) | Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration | |
| Sauneuf et al. | Clinical and EEG features of acute intrathecal baclofen overdose | |
| CN101400335A (zh) | 用于cns病症的治疗剂的稳定制剂的中枢给药 | |
| US11590105B2 (en) | Intrathecal administration of levetiracetam | |
| Hussain et al. | Analgesic Effects of Pre-induction Low-dose Ketamine on Post-tonsillectomy Patients | |
| Hydrochloride | Bupivacaine Hydrochloride | |
| Leuwer et al. | Neuromuscular blocking agents and skeletal muscle relaxants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20140725 |